A planned osteoporosis pill trial is expected to enroll about 900 women. Entera expects its first site to open in late 2026.

Entera Bio (ENTX) plans to initiate a Phase 3 trial for its osteoporosis drug EB613 in late 2026, with 900 women expected to enroll. The company presented Phase 2 data at ASBMR 2026, showing potential benefits for patients with low bone mineral density. Entera also announced key leadership appointments and financial results for Q3 2026.

Original reporting
Published Nov 6, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ENTX
Bullish
high confidence
Mentioned
$ENTX
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ENTXBullishMed
01

Why it matters

The disclosed Phase 3 design and enrollment target provide the first detailed view of the pivotal study, a key step toward regulatory approval.

02

Market read

First‑time detailed Phase 3 information for an oral osteoporosis therapy, a potentially transformative product in a large market.

03

What to watch

The partnership with OPKO for hypoparathyroidism and other pipeline programs may dilute focus on EB613.

Relevance 8/10Novelty 8/10Timing: late 2026 trial start

Background

Entera Bio is a clinical‑stage company developing oral peptide therapeutics, with EB613 as its lead osteoporosis candidate.

Company-level read

Ticker impact

$ENTXBullishHigh confidence
Context

Entera Bio announced its Phase 3 osteoporosis trial design and enrollment target of ~900 women, with first site activation planned for late 2026.

Expected impact

likely upward pressure as investors price in potential approval pathway.

Evidence & confidence

New Phase 3 data and FDA acceptance are material catalysts for a clinical‑stage biotech.

Market effects

Advances in oral peptide therapy could boost the broader biotech and osteoporosis treatment sectors.

US biotech investors may see increased interest in oral peptide platforms.

Potential global impact if oral osteoporosis therapy proves effective.

Counterpoint

If the Phase 3 trial faces enrollment delays or safety issues, the stock could face downside pressure.

Key entities

  • Entera Bio Ltd.

    Developer of oral peptide drugs, ticker ENTX.

  • OPKO Health

    Collaborator on EB612 hypoparathyroidism program.

Related articles

$ENTXMedAI 8/10

Entera Bio to present Phase 3 trial design for oral osteoporosis drug

Entera Bio (ENTX) will present Phase 3 trial design for its oral osteoporosis drug, EB613, at a conference in October 2026. The study will evaluate EB613 in postmenopausal women with osteoporosis. The company previously reported positive Phase 2 results, showing improvements in bone density and markers. EB613 is an oral, once-daily tablet, unlike current anabolic therapies that require injections.

$ENTXMed

Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)

Entera Bio (ENTX) received an 'Outperform' rating and $9 price target from Leerink Partners. The company's lead drug, EB613, is in development for osteoporosis and has completed Phase 2 trials. Entera recently raised $275M in funding and plans to initiate Phase 3 trials in late 2026, with data expected in 2028. ENTX was trading at $3.03 per share as of September 17, 2026.

$ENTXMedAI 8/10

Entera Bio Q2 EPS misses estimate as net loss widens to $7.3 million

Entera Bio Ltd. (NASDAQ: ENTX) reported Q2 2026 EPS loss of $0.14 versus a $0.08 consensus estimate, with net loss widening to $7.3 million from $2.7 million a year earlier, driven mainly by a $2.7 million non-cash warrant fair value remeasurement. The company also closed an oversubscribed $275 million private placement to fund EB613 Phase 3 NDA work through 2030.